ArticleMedComm2023
Interleukin-37 promotes DMBA/TPA skin cancer through SIGIRR-mediated inhibition of glycolysis in CD103
Open access · goldAbstract read
In one paragraph
Article in MedComm, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells.Oncoimmunology · 2026Review
- Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming.Signal transduction and targeted therapy · 2026Article
- Resistance to tumorigenesis in the african spiny mouse (Acomys) correlates with upregulation of multiple tumor suppressor genes.Scientific reports · 2026Article
- The complex role of IL-37 in cancer pathogenesis: exploring its influence on hallmarks of cancer.Frontiers in immunology · 2026Review
- Glycolysis in the tumor microenvironment shapes dendritic cell function and antitumor immunity.Frontiers in immunology · 2026Review
- Beyond Negative Regulation: IL-1R8 and IL-1R2 as Novel Immune Checkpoints.European journal of immunology · 2025Review
- SIGIRR: An Orphan Receptor Mediating Anti-inflammatory Actions.Expert reviews in molecular medicine · 2025Review
- A biodegradable capacitive-coupling neurostimulator for wireless electroceutical treatment of inflammatory bowel diseases.Science advances · 2025Article
- MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma.Nature communications · 2025Article
- CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma.Molecular medicine (Cambridge, Mass.) · 2024Article
- Role of IL-1 Family Cytokines IL-36, IL-37, IL-38 in Osteoarthritis and Rheumatoid Arthritis: A Comprehensive Review.Journal of inflammation research · 2024Review
- Interleukin-37 promotes DMBA/TPA skin cancer through SIGIRR-mediated inhibition of glycolysis in CD103MedComm · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 1 institution in 2 countries.
Fan-Lian ZengState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Xiao-Yan WangState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Ya-Wen HuState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Zhen WangState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.ORCID https://orcid.org/0000-0002-2516-4752
Ya LiState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Jing HuState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Jia-Dong YuState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Pei ZhouState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Xiu TengLaboratory of Human Disease and Immunotherapies West China Hospital Sichuan University Chengdu China.
Hong ZhouState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Hua-Ping ZhengState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Fu-Lei ZhaoState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Lin-Na GuState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Cheng-Cheng YueState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Shu-Wen ChenState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Juan ChengState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Yan HaoState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Qi-Xiang ZhaoState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Chen ZhangState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Song ZouDepartment of Cardiology West China Hospital Sichuan University Chengdu China.
Zhong-Lan HuState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Xiao-Qiong WeiState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Xiao LiuState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Guo-Lin LiState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Nong-Yu HuangState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Wen-Ling WuState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Yi-Fan ZhouState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.
Wei LiDepartment of Dermatovenereology West China Hospital Sichuan University Chengdu China.
Kaijun CuiDepartment of Cardiology West China Hospital Sichuan University Chengdu China.
Jiong LiState Key Laboratory of Biotherapy and Cancer Center West China Hospital West China Medical School Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu China.ORCID https://orcid.org/0000-0003-2320-9387
Sichuan University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin 37 (IL-37), a member of the IL-1 family, is considered a suppressor of innate and adaptive immunity and, hence is a regulator of tumor immunity. However, the specific molecular mechanism and role of IL-37 in skin cancer remain unclear. Here, we report that IL-37b-transgenic mice (IL-37tg) treated with the carcinogenic 7,12-dimethylbenzoanthracene (DMBA)/12-o-tetradecylphorbol-13-acetate (TPA) exhibited enhanced skin cancer and increased tumor burden in the skin by inhibiting the function of CD103
Indexed as
CD103+DCsglycolysisinterleukin‐37SIGIRRskin cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.